Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

97.46USD
1:31am IST
Change (% chg)

$-0.22 (-0.23%)
Prev Close
$97.68
Open
$98.14
Day's High
$98.40
Day's Low
$97.30
Volume
3,289,048
Avg. Vol
2,468,774
52-wk High
$109.49
52-wk Low
$95.10

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Company’s primary focus is products related to human health and... (more)

Overall

Beta: 0.56
Market Cap(Mil.): $270,871.09
Shares Outstanding(Mil.): 2,773.04
Dividend: 0.75
Yield (%): 3.07

Financials

  JNJ.N Industry Sector
P/E (TTM): 17.49 35.73 39.36
EPS (TTM): 5.59 -- --
ROI: 14.86 17.15 16.35
ROE: 22.04 18.03 17.47
Search Stocks

U.S. current account widens on weak exports, overseas profits

WASHINGTON - The U.S. current account deficit widened in the first quarter to its highest level since 2012 likely due to the strong dollar's drag on overseas profits and exports.

18 Jun 2015

U.S. industrial output hurt by weakness in manufacturing, mining

WASHINGTON - U.S. industrial production unexpectedly fell in May as manufacturing and mining activity remained weak, a sign that a strong dollar and spending cuts in the energy sector continued to constrain economic growth.

15 Jun 2015

WRAPUP 2-U.S. industrial output hurt by weakness in manufacturing, mining

WASHINGTON, June 15 - U.S. industrial production unexpectedly fell in May as manufacturing and mining activity remained weak, a sign that a strong dollar and spending cuts in the energy sector continued to constrain economic growth.

15 Jun 2015

Genmab shares rise on cancer drug's FDA licence application

COPENHAGEN, June 8 - Shares in Genmab rose almost 3 percent on Monday after partner Johnson and Johnson's announcement late on Friday that the companies have applied to U.S. authorities for a licence to market their blood cancer drug daratumumab.

08 Jun 2015

U.S. economy contracts in first quarter; dollar hurts corporate profits

WASHINGTON - The U.S. economy contracted in the first quarter as it buckled under the weight of unusually heavy snowfalls, a resurgent dollar and disruptions at West Coast ports, but activity already has rebounded modestly. | Video

30 May 2015

U.S. economy contracts in Q1; dollar hurts corporate profits

WASHINGTON - The U.S. economy contracted in the first quarter as it buckled under the weight of unusually heavy snowfalls, a resurgent dollar and disruptions at West Coast ports, but activity already has rebounded modestly.

29 May 2015

WRAPUP 4-U.S. economy contracts in Q1; dollar hurts corporate profits

WASHINGTON, May 29 - The U.S. economy contracted in the first quarter as it buckled under the weight of unusually heavy snowfalls, a resurgent dollar and disruptions at West Coast ports, but activity already has rebounded modestly.

29 May 2015

WRAPUP 2-U.S. economy contracts in Q1; dollar hits corporate profits

WASHINGTON, May 29 - The U.S. economy contracted in the first quarter as it buckled under the weight of unusually heavy snowfalls and a resurgent dollar, but activity has rebounded modestly.

29 May 2015

FBI probing what J&J knew about uterine surgery device: WSJ

- The Federal Bureau of Investigation is probing a surgical tool found to spread uterine cancer and what Johnson & Johnson knew about its risks before withdrawing its version of the device last year, the Wall Street Journal reported.

28 May 2015

FBI probing what J&J knew about uterine surgery device - WSJ

- The Federal Bureau of Investigation is probing a surgical tool found to spread uterine cancer and what Johnson & Johnson knew about its risks before withdrawing its version of the device last year, the Wall Street Journal reported.

28 May 2015

Earnings vs. Estimates

Search Stocks